Pharmacogenomics of human UDP-glucuronosyltransferases and irinotecan toxicity

Molecular Pharmacology

Volumn 62, Issue 3, 2002, Pages 446-450

  Tukey, Robert H ^a   Strassburg, Christian P ^b   Mackenzie, Peter I ^c  

^a San Diego   (United States)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c FLINDERS MEDICAL CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; GLUCURONOSYLTRANSFERASE; IRINOTECAN;

ANTINEOPLASTIC ACTIVITY; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG GLUCURONIDATION; DRUG METABOLISM; ENTEROPATHY; GASTROINTESTINAL TOXICITY; GENE EXPRESSION; HUMAN; LEUKOPENIA; NEUTROPENIA; PHARMACOGENOMICS; PRIORITY JOURNAL; REVIEW;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; DRUG INTERACTIONS; ENZYME ACTIVATION; FLAVONOIDS; GLUCURONOSYLTRANSFERASE; HUMANS; PHARMACOGENETICS;

EID: 0036765343     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.62.3.446     Document Type: Review

References (43)

1. Ando Y, Saka H, Ando M, Sawa T, Muro K, Ueoka H, Yokoyama A, Saitoh S, Shimokata K, and Hasegawa Y (2000) Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 60: 6921-6926.
2. Ando Y, Ueoka H, Sugiyama T, Ichiki M, Shimokata K, and Hasegawa Y (2002) Polymorphisms of UDP-glucuronosyltransferase and pharmacokinetics of irinotecan. Ther Drug Monit 24:111-116.
3. Atsumi R, Suzuki W, and Hakusui H (1991) Identification of the metabolites of irinotecan, a new derivative of camptothecin, in rat bile and its biliary excretion. Xenobiotica 21:1159-1169.
4. Bosma PJ, Chowdhury JR, Bakker C, Gantla S, De Boer A, Oostra BA, Lindhout D, Tytgat GNJ, Jansen PLM, Elferink RPJO, et al. (1995) The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med 333:1171-1175.
5. Ciotti M, Basu N, Brangi M, and Owens IS (1999) Glucuronidation of 7-ethyl-10 hydroxycamptothecin (SN-38) by the human UDP-glucuronosyltranferases encoded at the UGT1 locus. Biochem Biophys Res Communun 260:199-202.
6. Creemers GJ, Lund B, and Verweij J (1994) Topoisomerase I inhibitors: topotecan and irenotecan. Cancer Treat Rev 20:73-96.
7. Firvida JL, Irigoyen A, Vazquez-Estevez S, Diz P, Constenla M, Casal-Rubio J, Valladares-Ayerbes M, Castellanos J, Rodriguez R, and Balcells M (2001) Phase II study of irinotecan as first-line chemotherapy for patients with advanced colorectal carcinoma. Cancer 91:704-711.
8. Gagné J-F, Montminy V, Belanger P, Journault K, Gaucher G, and Guillemette C (2002) Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7 ethyl-10-hydroxycamptothecin (SN-38). Mol Pharmacol 62:608-617.
9. Galijatovic A, Otake Y, Walle UK, and Walle T (2001) Induction of UDP-glucuronosyltransferase UGT1A1 by the flavonoid chrysin in Caco-2 cells-potential role in carcinogen bioinactivation. Pharm Res 19:374-379.
10. Garcia-Carbonero R and Supko JG (2002) Current perspectives on the clinical experience, pharmacology and continued development of the camptothecins. Clin Cancer Res 8:641-661.
11. Gong QH, Cho JW, Huang T, Potter C, Gholami N, Basu NK, Kubota S, Carvalho S, Pennington MW, Owens IS, and Popescu NC (2001) Thirteen UDPglucuronosyltransferase genes we encoded at the human UGT1 gene complex locus. Pharmacogenetics 11:357-368.
12. Guillemette C, Ritter JK, Auyeung DJ, Kessler FK, and Housman DE (2000) Structural heterogeneity at the UDP-glucuronosyltransferase 1A locus: functional consequences of three novel missense mutations in the human UGT1A7 gene. Pharmacogenetics 10:629-644.
13. Ishihara T, Kaita M, Takeuchi K, Gabazza EC, Tanaka Y, Higuchi K, Ikoma J, Watanabe S, Sato H, and Adachi Y (2001) Role of UGT1A1 mutation in fasting hyperbilirubinemia. J Gastroenterol Hepatol 16:678-682.
14. Iyer L, King CD, Whitington PF, Green MD, Roy SK, Tephly TR, Coffman BL, and Ratain MJ (1998) Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest 101:847-854.
15. Iyer L and Ratain MJ (1998) Clinical pharmacology of camptothecins. Cancer Chemother Pharmacol 42 Suppl:S31-S43.
16. Kadakol A, Ghosh SS, Sappal BS, Sharma G, Chowdhury JR, and Chowdhury NR (2000) Genetic lesions of bilirubin uridine-diphosphoglucuronate glucuronosyl transferase (UGT1A1) causing Crigler-Nejjar and Gilbert syndromes: correlation of genotype to phenotype. Hum Mutat 16:297-306.
17. Kakolyris S, Kouroussis C, Souglakos J, Agelaki S, Kalbakis K, Vardakis N, Vamvakas L, and Georgoulias V (2001) Cisplatin and irinotecan (CPT-11) as second line treatment in patients with advanced non-small cell lung cancer. Lung Cancer 34 Suppl 4:71-76.
18. Kawato Y, Aonuma M, Hirota Y, Kuga H, and Sato K (1991) Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 51:4187-4191.
19. Kehrer DF, Sparreboom A, Verweij J, de Bruijn P, Nierop CA, van de SJ, Ruijgrok EJ and de Jonge MJ (2001) Modulation of irinotecan-induced diarrhea by cotreatment with neomycin in cancer patients. Clin Cancer Res 7:1136-1141.
20. Kobayashi IC Bouscarel B, Matsuzaki Y, Ceryak S, Kudoh S, and Fromm H (1999) pH-Dependent uptake of irinotecan and its active metabolite, SN-38, by intestinal cells. Int J Cancer 83:491-496.
21. Lampe JW, Bigler J, Horner NK and Potter JD (1999) UDP-Glucuronosyltransferase (UGT1A1*28 and UGT1A6*2) polymorphisms in Caucasians and Asians: relationships to serum bilirubin concentrations. Pharmacogenetics 9:341-349.
22. Mackenzie PI (1995) The UDP glucuronoslytransferase multigene family, in Reviews in Biochemical Toxicology (Hodgson E, Bend JR, and Philpot RM eds) pp 29-72, Taxicology Cummunications, Inc., Raleigh, NC.
23. Mackenzie, PI, Miners JO, and McKinnon RA (2000) Polymorphisms in UDP glucuronosyltransferase genes: functional consequences and clinical relevance. Clin Chem Lab Med 38:889-892.
24. Mackenzie PI, Owens IS, Burchell B, Bock KW, Bairoch A, Belanger A, Fournel-Gigleux S, Green M, Hum DW, Iyanagi T, et al. (1997) The UDP glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence. Pharmacogenetics 7:255-269.
25. Mathijssen RH, van Alphen RJ, Verweij J, Loos WJ, Nooter K, Stoter G, and Sparreboom A (2001) Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 7:2182-2194.
26. Ratain MJ (2000) Insights into the pharmacokinetics and pharmacodynamics irinotecan. Clin Cnncer Res 6:3393-3394.
27. Ritter JK Chen F, Sheen YY, Tran HM, Kimura S, Yeatman MT, and Owens IS (1992) A Novel complex locus UGT1 encodes human bilirubin, phenol and other UDP-glucuronosyltransferase isozymes with identical carboxyl termini. J Biol Chem 267:3257-3261.
28. Sasaki Y, Hakusui H, Mizuno S, Morita M, Miya T, Eguchi K, Shinkai T, Tamura T, Ohe Y, and Saijo N (1995) A pharmacokinetic MJ pharmacodynamic analysis of CPT-11 and its active metabolite SN-38. Jpn J Cancer Res 86:101-110.
29. Satoh, T, Hosokawa M, Atsumi R, Suzuki W, Hakusui H, and Nagai E (1994) Metabolic activation of CPT-11,7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin, a novel antitumor agent, by carboxylesterase. Biol Pharm Bull 17:662-664.
30. 14C]CPT-11 in cancer patients. Drug Metab Dispos 28:423-433.
31. Slatter JG, Su P, Sams JP, Schaaf LJ, and Wienkers LC (1997) Bioactivation of the anticancer agent CPT-11 to SN-38 by human hepatic microsomal carboxylesterases and the in vitro assessment of potential drug interactions. Drug Metab Dispos 25:1157-1164.
32. Strassburg CP, Kneip S, Topp J, Obermayer-Straub P, Barut A, Tukey RH, and Manns MP (2000) Polymorphic gene expression and interindividual variation of UDP-glucuronosyltransferase activity in human small intestine. J Biol Chem 46:36164-36171.
33. Strassburg CP, Manns MP, and Tukey RH (1998a) Expression of the UDP-glucuronosyltransferase 1A locus in human colon. Identification and characterization of the novel extrahepatic UGT1A8. J Biol Chem 273:8719-8726.
34. Strassburg CP, Nguyen N, Manns MP, and Tukey RH (1998b) Polymorphic expression of the UDP-glucuronosyltransferase UGT1A gene locus in human gastric epithelium. Mol Pharmacol 54:647-654.
35. Strassburg CP, Nguyen N, Manns MP, and Tukey RH (1999) UDP-glucuronosyltransferase activity in human liver and colon. Gastroenterology 116:149-160.
36. Strassburg CP, Vogel A, Kneip S, Tukey RH, and Manns M (2002) Polymorphisms of the human UDP-glucuronosyltransferase (UGT) 1A7 in colorectal cancer. Gut 6:851-856.
37. Tukey RH and Strassburg CP (2000) Human UDP-glucuronosyltransferases: metabolism, expression and disease. Annu Rev Pharmacol Toxicol 40:581-616.
38. Tukey RH and Strassburg CP (2001) Genetic multiplicity of the human UDP-glucuronosyltransferases and regulation in the gastrointestinal tract. Mol Pharmacol 59:405-414.
39. Vamvakas L, Kakolyris S, Kouroussis C, Kandilis K, Mavroudis D, Ziras N, Androulakis N, Kalbakis K, Sarra E, Souglakos J, et al. (2002) Irinotecan (CPT-11) in combination with infusional 5-fluorouracil and leucovorin (De Gramont Regimen) as first-line treatment in patients with advanced colorectal cancer: a multicenter phase II study. Am J Clin Oncol 25:65-70.
40. Vogel A, Kneip S, Barut A, Ehmer U, Tukey RH, Manns MP, and Strassburg CP (2001) Genetic link of hepatocellular carcinoma with polymorphisms of the UDP-glucuronosyltransferase UGT1A7 gene. Gastroenterology 121:1136-1144.
41. Walle UK, Galijatovic A, and Walle T (1999) Transport of the flavonoid chrysin and its conjugated metabolites by the human intestinal cell line Caco-2. Biochem Pharmacol 58:431-438.
42. Yamamoto W, Verweij J, de Bruijn P, de Jonge MJ, Takano H, Nishiyama M, Kurihara M, and Sparreboom A (2001) Active transepithelial transport of irinotecan (CPT-11) and its metabolites by human intestinal Caco-2 cells. Anticancer Drugs 12:419-432.
43. Zheng Z, Park JY, Guillemette C, Schantz SP, and Lazarus P (2001) Tobacco carcinogen-detoxifying enzyme UGT1A7 and its association with orolaryngeal cancer risk. J Natl Cancer Inst 93:1411-1418.